Evaluation of the efficacy of oral nano‐silymarin formulation in hospitalized patients with COVID‐19: A double‐blind placebo‐controlled clinical trial

Considering the outbreak pandemic of Coronavirus Disease 2019 (COVID‐19), the lack of effective therapeutic strategies for the management of this viral disease, and the increasing evidence on the antiviral potential of silymarin, this study aimed to investigate the effectiveness of silymarin nanomic...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2022-10, Vol.36 (10), p.3924-3931
Main Authors: Aryan, Hossein, Farahani, Ramin Hamidi, Chamanara, Mohsen, Elyasi, Sepideh, Jaafari, Mahmoud Reza, Haddad, Mahboubeh, Sani, Ashraf Tavanaee, Ardalan, Mohamed Afshar, Mosaed, Reza
Format: Article
Language:English
Subjects:
Alanine
Alanine transaminase
anti‐viral
Clinical trials
Coronaviruses
COVID-19
cytokine release syndrome
Dexamethasone
Double-blind studies
Health services
Laboratories
Pandemics
Parameters
Patients
Placebos
SARS‐COV‐2
Signs and symptoms
Silymarin
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Considering the outbreak pandemic of Coronavirus Disease 2019 (COVID‐19), the lack of effective therapeutic strategies for the management of this viral disease, and the increasing evidence on the antiviral potential of silymarin, this study aimed to investigate the effectiveness of silymarin nanomicelles on the symptom's resolution time, laboratory parameters, and liver enzymes in patients with COVID‐19. The participants were assigned to the nano‐silymarin (n = 25) (receiving SinaLive soft gel, containing 70 mg silymarin as nanomicelles) or placebo groups (n = 25) three times daily for two weeks. Patients' symptoms and laboratory findings were assessed at baseline and during the follow‐up period (one week and one month after the beginning of the treatment). No significant differences were observed between the two groups in terms of symptoms resolution time, laboratory parameters, and hospitalization duration (p > 0.05). However, the alanine aminotransferase level decreased significantly in the treatment group, compared to the placebo group (p 
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.7537